About

About OmniaBio Inc. OmniaBio Inc. is a specialized cell and gene therapy CDMO with a vision to manufacture a disease-free world. OmniaBio provides comprehensive services to therapeutic developers from early process development through to commercial manufacturing. As a CCRM subsidiary, OmniaBio builds on over a decade of expertise in regenerative medicine and advanced therapies, offering its clients extensive leadership in immune cell-based therapies, induced pluripotent stem cell-based therapies, and lentiviral vectors. With current clinical manufacturing capabilities, and a commercial manufacturing facility opening this summer, OmniaBio is poised to meet the surging global manufacturing demand, enabling access to transformative treatments for patients around the world. Visit us at www.omniabio.com. About OmniaBio Inc. OmniaBio Inc. is a specialized cell and gene therapy CDMO with a vision to manufacture a disease-free world. OmniaBio provides comprehensive services to therapeutic developers from early process development through to commercial manufacturing. As a CCRM subsidiary, OmniaBio builds on over a decade of expertise in regenerative medicine and advanced therapies, offering its clients extensive leadership in immune cell-based therapies, induced pluripotent stem cell-based therapies, and lentiviral vectors. With current clinical manufacturing capabilities, and a commercial manufacturing facility opening this summer, OmniaBio is poised to meet the surging global manufacturing demand, enabling access to transformative treatments for patients around the world. Visit us at www.omniabio.com. OmniaBio is redefining the future of cell therapy manufacturing through its proprietary AI-powered Intelligent Factory™. Purpose-built to accelerate discoveries and industrialize production, the Intelligent Factory™ integrates artificial intelligence and automation across the entire manufacturing lifecycle. With a focus on autologous CAR-T and other advanced therapies, OmniaBio’s platform enables scalable, efficient, and high-fidelity production by embedding predictive analytics, robotic bioprocessing, and digital quality systems into a unified, closed-loop system. This approach not only enhances throughput and consistency but also positions OmniaBio as a next-generation CDMO partner for innovators seeking to bring life-saving therapies to patients faster. OmniaBio Inc. is a subsidiary of the Centre for Commercialization of Regenerative Medicine (CCRM), which was founded in 2011 to support the development and commercialization of cell and gene therapies and regenerative medicine technologies. Since 2016, we have offered contract development and manufacturing organization (CDMO) services to our clients which draws on the extensive resources of both CCRM and various partners with a team comprised of approximately 300+ professionals, scientists, and engineers, with 60+ PhDs. OmniaBio and CCRM have a strong history in establishing and fostering long-term partnerships with clients, and our deep expertise and state-of-the-art facilities are ideally suited to projects requiring scale-up in various bioreactor geometries, process optimization, and bioprocess engineering. Our services are tailored to each client’s needs to enable the best possible value and outcomes, whether that’s quick entry into the clinic or developing a more optimized process to enable high throughput for clinical manufacturing. Once OmniaBio’s new facility begins opening in late 2024, it will be Canada’s first commercial-scale CDMO dedicated to cell and gene therapies. Based at the McMaster Innovation Park, OmniaBio will anchor a biomanufacturing centre of excellence and open in three phases between 2024 and 2027. Benefitting from CCRM’s existing infrastructure and expertise, OmniaBio will serve the full continuum of process and analytical development and manufacturing capabilities spanning preclinical process development through to commercial stage manufacturing.